Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flow from operating activities
Net (loss) income	$ (30,515)	$ 75,935
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Stock-based compensation expense	11,048	8,108
Depreciation	3,720	3,106
Impairment charge on leased facility	2,776
Amortization of premiums and discounts on marketable securities	(6,456)	(1,832)
Loss on disposal of fixed assets	478	143
Changes in operating assets and liabilities:
Accounts receivable	64,196
Related party collaboration receivable	(373)	(2,996)
Prepaid expenses and other current assets	(3,097)	(342)
Operating lease, right-of-use asset	3,423	1,459
Accounts payable	1,556	704
Accrued expenses	(5,381)	3,236
Operating lease liabilities	(1,698)	(2,102)
Deferred revenue	(40,458)	16,260
Net cash (used in) provided by operating activities	(781)	101,679
Cash flow from investing activities
Purchases of property and equipment	(3,366)	(2,501)
Purchases of marketable securities	(334,667)	(194,975)
Proceeds from sales and maturities of marketable securities	270,377	29,000
Net cash used in investing activities	(67,656)	(168,476)
Cash flow from financing activities
Proceeds from the exercise of stock options	261	1,829
Proceeds from the issuance of common stock in connection with the underwritten public offering	93,473
Proceeds from the issuance of common stock in connection with the 2023 Novartis Stock Purchase Agreement	19,305
Proceeds from the issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement		31,121
Proceeds from the purchase of common stock under ESPP	402	235
Net cash provided by financing activities	113,441	33,185
Net increase (decrease) in cash, cash equivalents, and restricted cash	45,004	(33,612)
Cash, cash equivalents, and restricted cash, beginning of period	70,395	100,474
Cash, cash equivalents, and restricted cash, end of period	115,399	$ 66,862
Supplemental disclosure of cash and non-cash activities
Operating lease right-of-use asset obtained in exchange for operating lease liability	$ 26,751